Cortexyme (CRTX) – Management Comments
-
Cortexyme (CRTX) Issues Pipeline Update and Anticipated 2022 Milestones
-
Cortexyme (CRTX) Reports Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis
-
-
-
Back to CRTX Stock Lookup